Sanofi’s Dupixent Has Greater Benefit In COPD Patients With Higher Type II Inflammation
Full Pivotal Data Suggests
The IL-4/IL-3 inhibitor attained a greater reduction in exacerbations in patients with a higher level of a biomarker for type 2 inflammation according to complete pivotal data, but questions remain on the timing of regulatory filings.
You may also be interested in...
The French drugmaker is banking on the wealth of expertise that Houman Ashrafian brings as both a scientist and biotech entrepreneur to drive forward its R&D efforts.
The 19 breakthrough therapy designations awarded so far this year run the gamut from areas that traditionally have not fared well with BTDs, like cardiovascular and respiratory disease, alongside the traditional cancer and orphan disease tentpoles.
Mepolizumab would be first drug for chronic obstructive pulmonary disorder to use eosinophil count as a biomarker, but FDA’s complete response letter says more clinical data are needed.